Needham & Company LLC reaffirmed their buy rating on shares of Crispr Therapeutics (NASDAQ:CRSP) in a research note issued to investors on Monday, December 23rd, AnalystRatings.com reports. They currently have a $84.00 price target on the stock.
CRSP has been the subject of several other research reports. BidaskClub downgraded shares of Crispr Therapeutics from a strong-buy rating to a buy rating in a research note on Friday, December 13th. TheStreet raised shares of Crispr Therapeutics from a d rating to a c rating in a research note on Monday, October 28th. Wells Fargo & Co reissued a buy rating on shares of Crispr Therapeutics in a research note on Friday, December 6th. Oppenheimer lifted their price target on Crispr Therapeutics from $65.00 to $80.00 and gave the company an outperform rating in a report on Monday, November 25th. Finally, Piper Jaffray Companies restated a buy rating and issued a $104.00 price target on shares of Crispr Therapeutics in a report on Monday, December 16th. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and twelve have issued a buy rating to the stock. The company presently has an average rating of Buy and an average price target of $71.38.
Shares of NASDAQ CRSP traded up $0.51 during trading on Monday, hitting $59.95. 1,011,477 shares of the company were exchanged, compared to its average volume of 1,376,743. The company has a market cap of $3.28 billion, a price-to-earnings ratio of -17.43 and a beta of 3.20. The company has a debt-to-equity ratio of 0.06, a current ratio of 8.32 and a quick ratio of 8.32. Crispr Therapeutics has a 1 year low of $29.34 and a 1 year high of $74.00. The firm’s fifty day moving average price is $66.14 and its 200 day moving average price is $51.34.
Crispr Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. The business had revenue of $211.93 million during the quarter, compared to the consensus estimate of $6.32 million. On average, research analysts forecast that Crispr Therapeutics will post 0.65 earnings per share for the current year.
In other Crispr Therapeutics news, President Rodger Novak sold 33,618 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the transaction, the president now owns 33,618 shares in the company, valued at approximately $2,353,260. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Pablo J. Cagnoni sold 7,500 shares of the company’s stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $52.00, for a total value of $390,000.00. Following the completion of the transaction, the director now owns 7,500 shares of the company’s stock, valued at approximately $390,000. The disclosure for this sale can be found here. Insiders have sold a total of 56,118 shares of company stock valued at $3,620,760 in the last quarter. Company insiders own 21.40% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Nikko Asset Management Americas Inc. boosted its holdings in Crispr Therapeutics by 48.4% in the 3rd quarter. Nikko Asset Management Americas Inc. now owns 2,777,414 shares of the company’s stock worth $113,846,000 after acquiring an additional 906,006 shares during the period. Price T Rowe Associates Inc. MD raised its position in shares of Crispr Therapeutics by 19.6% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock valued at $34,801,000 after purchasing an additional 121,176 shares in the last quarter. Wells Fargo & Company MN raised its position in shares of Crispr Therapeutics by 23.9% in the 2nd quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock valued at $28,443,000 after purchasing an additional 116,540 shares in the last quarter. Orbimed Advisors LLC acquired a new position in shares of Crispr Therapeutics in the 3rd quarter valued at approximately $21,167,000. Finally, Morgan Stanley raised its position in shares of Crispr Therapeutics by 6.1% in the 2nd quarter. Morgan Stanley now owns 284,984 shares of the company’s stock valued at $13,423,000 after purchasing an additional 16,361 shares in the last quarter. Hedge funds and other institutional investors own 49.82% of the company’s stock.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Further Reading: Recession
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.